NF-kappaB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells
- PMID: 12706838
- DOI: 10.1016/s0014-5793(03)00326-0
NF-kappaB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells
Abstract
4-1BB(CD137) is a member of the tumor necrosis factor receptor superfamily and provides a costimulatory signal by interaction with 4-1BB ligand expressed on antigen-presenting cells. The expression of 4-1BB is known to be activation-dependent. Here, we investigated the transcriptional machinery required for T cell receptor (TCR) activation-dependent induction of 4-1BB expression in CD3-CEM cells treated with phorbol myristate acetate and ionomycin. Using 5'-deletion constructs of 4-1BB promoter in luciferase reporter assays, we demonstrated that the transcriptional elements mediating 4-1BB upregulation were located in the region between approximately 0.9 and approximately 1.1 kb from the translational start site. Characterization of these sites by electrophoretic mobility shift assay and site-directed mutagenesis revealed that nuclear factor kappaB (NF-kappaB) and activating protein-1 (AP-1) are involved. MEK and c-Jun N-terminal kinase-1 activity was required for activation-dependent 4-1BB upregulation. Thus, NF-kappaB and AP-1 are involved in the TCR stimulation-dependent transcriptional regulation of the 4-1BB promoter.
Similar articles
-
Activation of c-jun N-terminal kinase by 4-1BB (CD137), a T cell co-stimulatory molecule.Mol Cells. 2000 Jun 30;10(3):247-52. Mol Cells. 2000. PMID: 10901161
-
Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B.Biochem Biophys Res Commun. 1998 Jan 26;242(3):613-20. doi: 10.1006/bbrc.1997.8016. Biochem Biophys Res Commun. 1998. PMID: 9464265
-
Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.Immunology. 2002 Dec;107(4):472-9. doi: 10.1046/j.1365-2567.2002.01538.x. Immunology. 2002. PMID: 12460192 Free PMC article.
-
Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
-
4-1BB: still in the midst of darkness.Mol Cells. 2000 Apr 30;10(2):119-26. doi: 10.1007/s10059-000-0119-0. Mol Cells. 2000. PMID: 10850651 Review.
Cited by
-
CD137 expression in cancer cells: regulation and significance.Cancer Commun (Lond). 2019 Nov 8;39(1):70. doi: 10.1186/s40880-019-0419-z. Cancer Commun (Lond). 2019. PMID: 31703738 Free PMC article. No abstract available.
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.J Immunother Cancer. 2022 Mar;10(3):e003532. doi: 10.1136/jitc-2021-003532. J Immunother Cancer. 2022. PMID: 35236742 Free PMC article.
-
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.Clin Cancer Res. 2020 Mar 15;26(6):1349-1358. doi: 10.1158/1078-0432.CCR-19-1068. Epub 2019 Dec 23. Clin Cancer Res. 2020. PMID: 31871298 Free PMC article.
-
Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells.Cancer Commun (Lond). 2019 Jul 9;39(1):41. doi: 10.1186/s40880-019-0386-4. Cancer Commun (Lond). 2019. PMID: 31288851 Free PMC article.
-
TLR7 induces anergy in human CD4(+) T cells.Nat Immunol. 2015 Jan;16(1):118-28. doi: 10.1038/ni.3036. Epub 2014 Nov 17. Nat Immunol. 2015. PMID: 25401424 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
